Appln. No. 10/642,289 Amd. dated November 1, 2005 Reply to Office Action of July 1, 2005

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:
Listing of Claims:

Claims 1-12 (Cancelled).

- 13. (New) An isolated polypeptide comprising an amino acid sequence at least 90% identical to the sequence of SEO ID NO: 2.
- 14. (New) The isolated polypeptide of claim 13 comprising an amino acid sequence at least 95% identical to the sequence of SEQ ID NO: 2.
- 15. (New) The isolated polypeptide of claim 13 comprising the amino acid sequence of SEQ ID NO: 2.
- 16. (New) A method for recombinantly producing the polypeptide according to claim 13 comprising:
- (a) culturing a host cell under conditions in which the host cell expresses the polypeptide; and
  - (b) isolating the polypeptide.
- 17. (New) A composition comprising the polypeptide according to claim 13, together with one or more pharmaceutically acceptable carriers and/or diluents.

Appln. No. 10/642,289 Amd. dated November 1, 2005 Reply to Office Action of July 1, 2005

- 18. (New) An isolated polypeptide encoded by the nucleotide sequence comprising the sequence of SEQ ID NO: 1 or a nucleotide sequence capable of hybridizing to the sequence of SEQ ID NO: 1 under high stringency conditions of about 31% v/v to about 50% v/v formamide, about 0.01M to about 0.15M salt and about 40°C to about 65°C, wherein said polypeptide has a sphingosinc kinase activity.
- 19. (New) The isolated polypeptide according to claim 18 encoded by a nucleic acid molecule at least 90% identical to the sequence of SEQ ID NO: 1.
- 20. (New) The isolated polypeptide according to claim 18 encoded by a nucleic acid molecule at least 95% identical to the sequence of SEQ ID NO: 1.
- 21. (New) A method for recombinantly producing the polypeptide according to claim 18 comprising:
- (a) culturing a host cell under conditions in which the host cell expresses the polypeptide; and
  - (b) isolating the polypeptide.
- 22. (New) A composition comprising the polypeptide according to claim 18, together with one or more pharmaceutically acceptable carriers and/or diluents.

- 4 -

Appln. No. 10/642,289 Amd. dated November 1, 2005 Reply to Office Action of July 1, 2005

- 23. (New) An isolated polypeptide, the polypeptide comprising at least 30 contiguous amino acid residues of amino acid residues 1 to 105 of SEQ ID NO: 2.
- 24. (New) An isolated polypeptide, the polypeptide comprising at least 50 contiguous amino acid residues of amino acid residues 1 to 105 of SEQ ID NO: 2.
- 25. (New) A composition comprising the polypeptide of claim 23, together with one or more pharmaceutically acceptable carriers and/or diluents.

- 5 -